We observed highly increased p-ERK levels in response to a 20 h treatment with the eIF4A helicase inhibitor in both melanoma subtypes (Fig. 2A), despite the presence of strong oncogenic BRAF and NRAS mutations already highly activating the ERK pathway in these cells. The gene discussed is MAPK1; the disease is melanoma.